Dr Reddys Laboratories Stock Alpha and Beta Analysis

RDY Stock  USD 14.48  0.00  0.00%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Dr Reddys Laboratories. It also helps investors analyze the systematic and unsystematic risks associated with investing in Dr Reddys over a specified time horizon. Remember, high Dr Reddys' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Dr Reddys' market risk premium analysis include:
Beta
(0.04)
Alpha
(0.16)
Risk
1.26
Sharpe Ratio
(0.1)
Expected Return
(0.12)
Please note that although Dr Reddys alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Dr Reddys did 0.16  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Dr Reddys Laboratories stock's relative risk over its benchmark. Dr Reddys Laboratories has a beta of 0.04  . As returns on the market increase, returns on owning Dr Reddys are expected to decrease at a much lower rate. During the bear market, Dr Reddys is likely to outperform the market. Book Value Per Share is likely to rise to 527.34 in 2024. Tangible Book Value Per Share is likely to rise to 392.73 in 2024.

Dr Reddys Quarterly Cash And Equivalents

13.54 Billion

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Dr Reddys Backtesting, Dr Reddys Valuation, Dr Reddys Correlation, Dr Reddys Hype Analysis, Dr Reddys Volatility, Dr Reddys History and analyze Dr Reddys Performance.

Dr Reddys Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Dr Reddys market risk premium is the additional return an investor will receive from holding Dr Reddys long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Dr Reddys. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Dr Reddys' performance over market.
α-0.16   β-0.04

Dr Reddys expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Dr Reddys' Buy-and-hold return. Our buy-and-hold chart shows how Dr Reddys performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Dr Reddys Market Price Analysis

Market price analysis indicators help investors to evaluate how Dr Reddys stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Dr Reddys shares will generate the highest return on investment. By understating and applying Dr Reddys stock market price indicators, traders can identify Dr Reddys position entry and exit signals to maximize returns.

Dr Reddys Return and Market Media

The median price of Dr Reddys for the period between Wed, Sep 18, 2024 and Tue, Dec 17, 2024 is 15.28 with a coefficient of variation of 4.64. The daily time series for the period is distributed with a sample standard deviation of 0.7, arithmetic mean of 15.15, and mean deviation of 0.65. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Investors three-year losses continue as Asymchem Laboratories dips a further 5.2 percent this week, earnings continue to decline
11/26/2024
2
Carl P. Sherr Co. LLC Makes New Investment in Abbott Laboratories
11/29/2024
3
Tri Chemical Laboratories Third Quarter 2025 Earnings Revenues Beat Expectations, EPS Lags
12/04/2024
4
Revance Therapeutics once again tries to go private with Crown Laboratories merger
12/09/2024
5
On Target Laboratories Appoints Bill Peters as CEO
12/10/2024
6
Kraig Biocraft Laboratories Reports Record-Setting Recombinant Spider Silk Production in 2024
12/11/2024
7
Soitec continues its collaboration with MITs Microsystems Technology Laboratories, thereby strengthening its presence in the United States
12/12/2024
8
Dr. Reddys SWOT analysis generics giant eyes biosimilars growth
12/13/2024

About Dr Reddys Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including RDY or other stocks. Alpha measures the amount that position in Dr Reddys Laboratories has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2023 2024 (projected)
Dividend Yield0.0063920.006073
Price To Sales Ratio3.733.91

Dr Reddys Upcoming Company Events

As portrayed in its financial statements, the presentation of Dr Reddys' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dr Reddys' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Dr Reddys' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Dr Reddys. Please utilize our Beneish M Score to check the likelihood of Dr Reddys' management manipulating its earnings.
31st of January 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

Build Portfolio with Dr Reddys

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for RDY Stock Analysis

When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.